Terms: = Leukemia AND ELK4, SAP1, 2005, ENSG00000158711, P28324 AND Treatment
606 results:
1. Impact of Fee For Service on the Efficiency and Survival of Seguro Popular's Patients With Acute Lymphoblastic leukemia in Mexico.
Cerecero-García D; Macías-González F; Muñoz-Aguirre P; Huerta-Gutierrez R; Zapata M; Rivera-Luna R; Lajous M; Bautista-Arredondo S
JCO Glob Oncol; 2024 May; 10():e2300060. PubMed ID: 38754053
[TBL] [Abstract] [Full Text] [Related]
2. Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
Muthiah C; Narra R; Atallah E; Juan W; Szabo A; Guru Murthy GS
Leuk Res; 2024 May; 140():107496. PubMed ID: 38547577
[TBL] [Abstract] [Full Text] [Related]
3. Predictive factors for L-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia.
Choed-Amphai C; Khorana J; Sathitsamitphong L; Natesirinilkul R; Charoenkwan P
Int J Hematol; 2024 Apr; 119(4):442-449. PubMed ID: 38421487
[TBL] [Abstract] [Full Text] [Related]
4. Increase in the Life Expectancy of Patients with Cancer in the United States.
Devasia TP; Howlader N; Dewar RA; Stevens JL; Mittu K; Mariotto AB
Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):196-205. PubMed ID: 38015774
[TBL] [Abstract] [Full Text] [Related]
5. A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy.
Jung YS; Son M; Lee SG; Chong JW; Kim SJ; Jang JE; Lyu CJ; Hahn SM; Han JW; Park K
Br J Clin Pharmacol; 2024 Mar; 90(3):849-862. PubMed ID: 37984417
[TBL] [Abstract] [Full Text] [Related]
6. Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States.
Shen C; Thornton JD; Li N; Schaefer E; Zhou S; Kawasaki S; Pameijer C; Leslie D
Oncologist; 2024 Feb; 29(2):176-184. PubMed ID: 37944042
[TBL] [Abstract] [Full Text] [Related]
7. Impact of multimorbidity and polypharmacy on mortality after cancer: a nationwide registry-based cohort study in Denmark 2005-2017.
Thomsen MK; Løppenthin KB; Bidstrup PE; Andersen EW; Dalton S; Petersen LN; Pappot H; Mortensen CE; Christensen MB; Frølich A; Lassen U; Johansen C
Acta Oncol; 2023 Dec; 62(12):1653-1660. PubMed ID: 37874076
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract] [Full Text] [Related]
9. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
Sasaki K; Haddad FG; Short NJ; Jain N; Issa G; Jabbour E; Kantarjian H
Cancer; 2023 Dec; 129(23):3805-3814. PubMed ID: 37769040
[TBL] [Abstract] [Full Text] [Related]
10. A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
Marcelletti JF; Sikic BI
Cancer Chemother Pharmacol; 2023 Nov; 92(5):369-380. PubMed ID: 37603048
[TBL] [Abstract] [Full Text] [Related]
11. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract] [Full Text] [Related]
12. Cytogenetically Normal Acute Myeloid Leukaemia at a Single Centre in South Africa.
Jenkins N; Blanshard LA; Stone M; Verburgh E; Oosthuizen J; Shires K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):397-406. PubMed ID: 37363984
[TBL] [Abstract] [Full Text] [Related]
13. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.
Mishra R; Dima D; Kumar SA; Mian A; Taneja A; Karna R; Caimi PF; Hill BT; Dean R; Jagadeesh D
Hematol Oncol; 2023 Dec; 41(5):884-893. PubMed ID: 37309225
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic leukemia.
Wang Y; Xue YJ; Jia YP; Zuo YX; Lu AD; Zhang LP
Acta Haematol; 2023; 146(5):349-357. PubMed ID: 37212472
[TBL] [Abstract] [Full Text] [Related]
15. Ponatinib vs. Imatinib as Frontline treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic leukemia: A Matching Adjusted Indirect Comparison.
Ribera JM; Prawitz T; Freitag A; Sharma A; Dobi B; Rizzo F; Sabatelli L; Patos P
Adv Ther; 2023 Jul; 40(7):3087-3103. PubMed ID: 37208556
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Analysis of Pediatric T-Cell Acute Lymphoblastic leukemia Using the MRD-Oriented Strategy System.
Xue YJ; Wang Y; Lu AD; Jia YP; Zuo YX; Ding MM; Zeng HM; Zhang LP
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):477-483. PubMed ID: 37080879
[TBL] [Abstract] [Full Text] [Related]
17. Frequency and pattern of chromosomal abnormalities in acute myeloid leukemia from Western India: A retrospective study.
Vundinti BR; Korgaonkar S; Dhangar S; Jijina F; Shanmukhaiah C
J Cancer Res Ther; 2023; 19(2):340-346. PubMed ID: 37006070
[TBL] [Abstract] [Full Text] [Related]
18. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood
van Weelderen RE; Klein K; Harrison CJ; Jiang Y; Abrahamsson J; Arad-Cohen N; Bart-Delabesse E; Buldini B; De Moerloose B; Dworzak MN; Elitzur S; Fernández Navarro JM; Gerbing RB; Goemans BF; de Groot-Kruseman HA; Guest E; Ha SY; Hasle H; Kelaidi C; Lapillonne H; Leverger G; Locatelli F; Masetti R; Miyamura T; Norén-Nyström U; Polychronopoulou S; Rasche M; Rubnitz JE; Stary J; Tierens A; Tomizawa D; Zwaan CM; Kaspers GJL
J Clin Oncol; 2023 Jun; 41(16):2963-2974. PubMed ID: 36996387
[TBL] [Abstract] [Full Text] [Related]
19. treatment outcomes in childhood acute lymphoblastic leukemia: 40-year experience from a single tertiary center in Thailand.
Chavananon S; Sripornsawan P; Songthawee N; McNeil EB; Chotsampancharoen T
Pediatr Hematol Oncol; 2023; 40(8):739-751. PubMed ID: 36940098
[TBL] [Abstract] [Full Text] [Related]
20. Early post-induction augmented therapy improves outcome in children and adolescents with T-cell acute lymphoblastic leukemia.
Abu Shanap M; Al Jabour H; Rihani R; Hashem H; Abu Ghosh A; Tbakhi A; Kamal N; Sultan I; Madanat F
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1703. PubMed ID: 36806723
[TBL] [Abstract] [Full Text] [Related]
[Next]
